GSK's Nucala (mepolizumab) Receives the US FDA's Approval as the First Treatment for Hypereosinophilic Syndrome
Shots:
- The approval is based on pivotal P-III study assessing Nucala (300mg- SC- q4w) + SOC vs PBO + SOC in 108 patients aged ≥12yrs.with uncontrolled HES for 32 wks.
- Results: The pivotal P-III study demonstrated 50% fewer patients experienced a HES flare 28% vs 56%). The approval follows a PR of data from a clinical development program that included positive results from a pivotal P-III study
- Mepolizumab is a mAb targeting IL-5- it works by preventing IL-5 from binding to its receptor on the surface of eosinophils- reducing blood eosinophils to normal levels & it is first approved in 2015 for severe eosinophilic asthma
Ref: GSK | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com